Chris Lewis


Roth Capital Reiterates Buy On Natus Medical; Raises PT To $36

In a research report issued to investors today, Roth Capital analyst Chris Lewis reiterated a Buy rating on Natus Medical (NASDAQ:BABY) and slightly …

Roth Capital Assigns Buy On Align Technology Shares, $66 PT

In a research report issued today, Roth Capital analyst Chris Lewis assigned a Buy rating on Align Technology (NASDAQ:ALGN) with a price target …

Roth Capital Assigns Buy On Natus Medical, $33 PT

In a research report issued today, Roth Capital analyst Chris Lewis assigned a Buy rating on Natus Medical (NASDAQ:BABY) with a price target …

Exact Sciences: CMS Reimbursement Likely At $502 – Significant Win, Says Roth Capital

In a research report released Friday, Roth Capital analyst Chris Lewis reiterated a Buy rating on Exact Sciences (NASDAQ:EXAS) and raised his price target to …

Roth Capital Assigns Buy On Masimo Following Patent Victory

In a research report released Friday, Roth Capital analyst Chris Lewis assigned a Buy rating on Masimo Corp. (NASDAQ:MASI) with a $29 price target, following …

Roth Capital Reiterates Buy On Volcano Shares, $16 PT

In a research report issued today, Roth Capital analyst Chris Lewis reiterated a Buy rating on Volcano (NASDAQ:VOLC) with a price target of …

Roth Capital Maintains Buy On Enteromedics Following CE Mark Expansion

In a research report issued today, Roth Capital analyst Chris Lewis maintained a Buy rating on Enteromedics (NASDAQ:ETRM) with a $5 price target, following today’s …

Roth Capital Highlights Key Takeaways From Tearlab’s Analyst Day

In a research note released earlier today, Roth Capital analyst Chris Lewis reiterated a Buy rating on Tearlab (NASDAQ:TEAR) with an $8 price target, following TEAR’s …

Roth Capital Reiterates Buy On TearLab Ahead Of Next Week’s Analyst Day

In a research note published today, Roth Capital analyst Chris Lewis reiterated a Buy rating on TearLab Corporation (NASDAQ:TEAR) with an $8 price target, …

Roth Capital Reaffirms Buy On Natus Medical Following Management’s Update Presentation

In a research note published today, Roth Capital analyst Chris Lewis reiterated a Buy rating on Natus Medical (NASDAQ:BABY) with a $33 price …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts